-
New CAR T-Cell Trial Targets Childhood Rhabdomyosarcoma
A new clinical trial is testing FGFR4-targeted CAR T-cell therapy in children and young adults with recurrent or hard-to-treat rhabdomyosarcoma, offering a novel immune-based approach for patients who need more options.
-
New Phase I Trial Launches to Evaluate AUBE00 for Advanced Solid Tumors
A first-in-human, multinational Phase I study is now underway to assess the safety, tolerability, and early anti-tumor activity of the investigational peptide-based therapy AUBE00 in patients with advanced or metastatic solid tumors.
-
New Clinical Trial Explores Combining Quad Shot Radiotherapy With Immunotherapy for Lung Cancer
A new study is testing whether adding a short, cyclical radiotherapy technique to immunotherapy and chemotherapy before surgery can help eliminate tumors in patients with stage II-III non-small cell lung cancer.
-
FDA Advisory Committee Signals Favorable Stance on Compounded Peptides
During the first day of a closely watched FDA advisory committee meeting on compounding, peptides received notably favorable discussion, suggesting continued access to these therapies through compounding pharmacies.
-
New Approach to Measuring C-Peptide Could Improve Type 1 Diabetes Trials
A proposed longitudinal C-peptide endpoint may offer researchers a more sensitive and informative way to evaluate treatments aimed at preserving insulin production in type 1 diabetes trials.
-
TwoStep Therapeutics Secures $62.5 Million Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate
TwoStep Therapeutics has closed an oversubscribed $62.5 million Series A financing round and received FDA clearance to begin clinical trials of its first-in-class peptide-drug conjugate therapy.
-
New Phase I Trial Launches for Novel WRN-Targeting Peptide-Based Therapy in Advanced Cancers
A first-in-human trial is now testing VVD-133214, an oral compound designed to target the Werner (WRN) protein, offering new hope for patients with MSI and dMMR advanced solid tumors.
-
New Clinical Trial Explores Enhanced Combination Therapy for Lymphoma Patients
A new study is investigating whether adding zilovertamab vedotin to standard chemotherapy could help newly diagnosed DLBCL patients live longer without cancer progression. The trial compares this combination against the current standard treatment regimen.
-
New Clinical Trial Explores Xeomin’s Potential to Prevent Episodic Migraine
A new clinical trial is underway to evaluate whether Xeomin injections can help reduce monthly migraine days in people with episodic migraine, compared to placebo.
-
New Phase 3 Trial Launches to Explore Novel Antibody-Drug Conjugate for Advanced Colorectal Cancer
A large global Phase 3 trial is now underway comparing an investigational antibody-drug conjugate, telisotuzumab adizutecan, plus bevacizumab against standard therapy for refractory metastatic colorectal cancer, offering new hope for patients with limited treatment options.